Kiniksa Pharmaceuticals, which is developing therapies for inflammatory and autoimmune conditions, raised $153 million by offering 8.48 million shares at $18, within the range of $17 to $19. The company offered 21% more shares than originally planned, or $26 million more in proceeds. In the most recent filing, insiders had indicated on $50 million of the IPO. At the $18 offer price, Kiniksa commands a fully diluted market value of $931 million. Kiniksa Pharmaceuticals plans to list on the Nasdaq under the symbol KNSA. Goldman Sachs and J.P. Morgan acted as lead managers on the deal.
